Walvax Strengthens Commitment to African Vaccine Manufacturing at EVMA Inaugural Event
(November 29, 2024, Kunming) - Walvax Biotechnology Co., Ltd. ("Walvax", together with its subsidiaries, the "Group", stock code: 300142.SZ), a leading vaccine developer and manufacturer from China, was honored to attend the Inaugural Event of Egyptian Vaccine Manufacturers Alliance (EVMA) in Cairo, highlighting its ongoing commitment to advancing vaccine manufacturing capabilities across Africa.
The event, themed the National Strategy for Vaccine Manufacturing Localization, officially launched the Egyptian Vaccine Manufacturers Alliance, an initiative that aims to localize vaccine production and expand exports across Africa.
As a key technology transfer provider, Walvax outlined the company's strategic approach to vaccine manufacturing and technology transfer in Africa. During the event, Walvax highlighted the company's robust global manufacturing network, demonstrating its technical expertise and global reach. Walvax showcased two successful, completed cases of local production, illustrating its proven experience and expertise in technology transfer across different vaccine products. These examples underscored Walvax's capability to support local manufacturing initiatives in emerging markets.
A central focus of the event was the announcement of several strategic partnerships in local vaccine production, among which, Walvax signed memorandum of understanding on site with two local Egyptian pharmaceutical companies, Vacsera and VBC. Walvax will collaborate with Vacsera to produce meningococcal vaccines in Egypt, and collaborate with VBC to empower local production of PCV13 and HPV2 vaccines. Through strategic cooperation, Walvax and its partners aim to build Egypt into the Africa regional vaccine manufacturing hub. These partnerships represent significant steps toward establishing sustainable vaccine manufacturing capabilities, to provide affordable and accessible vaccines to the country and the continent.
The collaborations align with China's Belt and Road Initiative, demonstrating Walvax's commitment to fostering international cooperation and supporting public health development along the Belt and Road countries. These initiatives will not only benefit Egypt but will also contribute to better health and wellness across the African continent.
The event was supported by the Unified Procurement Authority, Egyptian Drug Authority, and the Ministry of Health and Population of Egypt, demonstrating the strong governmental backing for advancing local vaccine manufacturing capabilities.
About Walvax
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from conventional vaccines to innovative vaccines. Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 22 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.